Supraventricular tachycardia in neonates: antiarrhythmic drug choice dilemma.
Supraventricular tachycardia (SVT), being atrioventricular reentry the underlying mechanism, is the most frequently tachyarrhythmia requiring a medical treatment in infants with no cardiac disease. The acute treatment of a single episode of SVT has generally an excellent prognosis. An antiarrhythmic prophylaxis of SVT recurrences is usually recommended during the first year of life. Although many efficient drugs are available for the SVT treatment, a careful risk-benefit analysis of each single case should suggest the correct drug choice.
Tavera
M C
MC
Division of Paediatric Cardiology, G. Brotzu Hospital, Cagliari, Italy.
Bassareo
P P
PP
Neroni
P
P
Follese
C
C
Manca
D
D
Montis
S
S
Tumbarello
R
R
D000889:Anti-Arrhythmia Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D018890:Chemoprevention / Q000379:methods; D002755:Choice Behavior; D003657:Decision Making; D004305:Dose-Response Relationship, Drug; D006801:Humans; D007231:Infant, Newborn; D018570:Risk Assessment; D013617:Tachycardia, Supraventricular / Q000151:congenital* / Q000188:drug therapy*
D000889:Anti-Arrhythmia Agents